A Randomized, Single-blind, Placebo-controlled, Four-way Crossover Thorough QT Study to Investigate the Effect of KP-001 on the QT/QTc Interval Using Open-label Moxifloxacin As an Active Control, in Adult Healthy Volunteers
Latest Information Update: 08 Apr 2025
At a glance
- Drugs ART-001 (Primary) ; Moxifloxacin
- Indications Vascular disorders
- Focus Therapeutic Use
- Sponsors Kaken Pharmaceutical
Most Recent Events
- 07 Mar 2025 Planned End Date changed from 11 Feb 2025 to 24 Apr 2025.
- 07 Mar 2025 Planned primary completion date changed from 7 Feb 2025 to 20 Mar 2025.
- 07 Mar 2025 Status changed from recruiting to active, no longer recruiting.